Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00716742 · ClinicalTrials.gov registry record
Safety and Efficacy Study of Bimatoprost, Latanoprost, and Travoprost in Patients With Elevated Intraocular Pressure (IOP) and Open-angle Glaucoma (OAG)
A clinical trial, sponsored by Allergan.
- Completed
- Registry status
- 1,099
- Enrollment target
NCT00716742 is a clinical trial that has completed, run by Allergan. The registered enrollment target is 1,099 participants.
The verdict
NCT00716742 has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- 1,099 participants
- Enrollment target
Study Summary
To investigate the effectiveness of the newer IOP-lowering therapies, as prescribed in normal clinical practice, in larger patient numbers. Patients will be assessed at baseline, at each follow-up visit (follow-up visits are variable as per physician discretion) and at final follow-up visit.
Interventions
- DRUG bimatoprost 0.03%, latanoprost 0.005%, and travoprost 0.004%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,099 participants |
| Start Date | 2004-09 |
| Est. Completion | 2009-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00716742
The ClinicalTrials.gov registry entry for NCT00716742 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,099 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which bimatoprost 0.03%, latanoprost 0.005%, and travoprost 0.004% is the first listed.
NCT00716742 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00716742 about?
NCT00716742 is a clinical study titled "Safety and Efficacy Study of Bimatoprost, Latanoprost, and Travoprost in Patients With Elevated Intraocular Pressure (IOP) and Open-angle Glaucoma (OAG)". To investigate the effectiveness of the newer IOP-lowering therapies, as prescribed in normal clinical practice, in larger patient numbers. Patients will be assessed at baseline, at each follow-up visit (follow-up visits are variable as per physician discretion) and at final follow-up visit.
What is the current status of trial NCT00716742?
This trial is currently completed. The enrollment target is 1,099 participants. The study started on 2004-09. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00716742?
The interventions under investigation include: bimatoprost 0.03%, latanoprost 0.005%, and travoprost 0.004% (DRUG).
Who is sponsoring clinical trial NCT00716742?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.